Mosenzon, Ofri
Capehorn, Matthew S.
De Remigis, Alessandra
Rasmussen, Søren
Weimers, Petra
Rosenstock, Julio
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
https://doi.org/10.2337/dc17-0417
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
https://doi.org/10.1186/s12933-022-01585-7
Documents that mention this clinical trial
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
https://doi.org/10.1186/s12933-022-01585-7
Documents that mention this clinical trial
1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5
https://doi.org/10.2337/db19-1004-p
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
https://doi.org/10.1007/s13300-020-00994-9
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
https://doi.org/10.1186/s12933-022-01585-7
Documents that mention this clinical trial
670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial
https://doi.org/10.2337/db21-670-p
1163-P: Cost Effectiveness of Oral Semaglutide 14mg vs. Empagliflozin 25mg in Canada
https://doi.org/10.2337/db20-1163-p
54-OR: Oral Semaglutide vs. Empagliflozin Added On to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2
https://doi.org/10.2337/db19-54-or
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
https://doi.org/10.1007/s41669-023-00416-z
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial (Results)
https://doi.org/10.2337/dc19-0883
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
https://doi.org/10.1186/s12933-022-01585-7
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 26 April 2022
Accepted: 27 July 2022
First Online: 2 September 2022
Declarations
:
: All trial protocols were approved by local independent ethics committees and institutional review boards at each site and trials were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. All subjects provided written, informed consent prior to trial start.
: Not applicable.
: OM reports personal fees for advisory board consultancy and speaker’s bureau from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, and Sanofi; and research grant support from AstraZeneca and Novo Nordisk. MC reports being a partner at Clifton Medical Centre, a director at RIO Weight Management, Ltd, and a consultant for LighterLife and McDonald’s; he also reports research funding from Abbott, Boehringer Ingelheim/Lilly Alliance, Janssen, MSD, and Novo Nordisk; advisory board consultancy, consultancy and honoraria from Abbott, Boehringer Ingelheim/Lilly Alliance, and Novo Nordisk; and meeting support from Boehringer Ingelheim/Lilly Alliance and Novo Nordisk. ADR, SR, and PW are full-time employees of Novo Nordisk; SR also owns shares in Novo Nordisk. JR reports research funding from Applied Therapeutics Inc., Boehringer Ingelheim, Eli Lilly, Genentech, GlaxoSmithKline, Hanmi, Intarcia, Janssen, Lexicon, Merck, Metacrine, Novo Nordisk, Novartis, Oramed, Pfizer, and Sanofi; and advisory board consultancy, consultancy, and honoraria from Applied Therapeutics Inc., Boehringer Ingelheim, Eli Lilly, Hanmi, Intarcia, Janssen, Novo Nordisk, Oramed, Sanofi, and Zealand.